Along with its many notable advantages, lentiviral vectors' attractiveness lies in their ability to be used in a wide range of cell and gene therapy indications, beyond rare diseases to serve larger patient populations. Recent regulatory approvals and clinical trial successes have led to a growing pipeline and interest in therapies using lentiviral vectors. And with that, an increased need for a robust, scalable production technology that improves overall yield and quality.
In this webinar, our upstream and downstream innovation scientists will explore how they optimized our VirusExpress® production technology for lentiviral vectors to maximize titer while providing a streamlined platform to accelerate development timelines to clinical trials.
In this webinar, you will learn how our VirusExpress® production technology:
- Offers optimized upstream and downstream workflows for lentiviral-based production
- Provides a streamlined, consistent production technology to seamlessly and robustly scale up to commercial manufacturing
- Reduces time to clinical/commercial manufacturing
Speakers
Hiral Gami
Merck
Upstream Scientist - Viral Vector Technology and Innovation
Hiral Gami is an upstream scientist in Merck's viral vector technology and innovation team based in Bedford, MA. She joined our company in January 2018 and has contributed to the development of cell retention devices (CRD) for perfusion bioreactors, along with generating application data to support the launch of the cell retention device and system. Since June 2019, she has been a part of the viral gene therapy - upstream group, where she is actively involved in developing and optimizing processes for viral vector production & scale-up. She holds a B.S. and M.S. in microbiology from Gujarat University, India, and an M.S. in biological sciences, biotechnology from UMASS, Lowell.
John Mumira
Merck
Application Scientist - Viral Vector Technology and Innovation
John Mumira is an application scientist with our viral vector technology and innovation team in Bedford, MA. He is currently working on viral vector production & scale-up process development and optimization as part of the upstream bioprocessing team. John has been in the life science industry for more than 18 years, focused on product development and process optimization. He holds a B.S. in biomedical laboratory and clinical sciences from Boston University.
Paul Turiano
Merck
Scientist - Viral Vector Technology and Innovation
Paul Turiano joined Merck in 2017 and is a scientist in the viral vector technology and innovation team. Paul is the tech lead for optimizing the tangential flow filtration step for lentiviral vectors. He also contributed to improving lentivirus clarification and chromatography unit operations. Paul previously worked in the chromatography team, where he developed affinity membrane chromatography technology for the Natrix project and optimized affinity ligands for Eshmuno®A resin. Paul holds a B.S. in biology from Case Western Reserve University.
Pharma and biopharma manufacturing
- Viral Vector Vaccine Manufacturing
Duration:1h
語言:English
會話 1:提出 July 13, 2023
若要繼續閱讀，請登入或建立帳戶。
還沒有帳戶？